Showing results (4501-4510 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|August 28, 2012
The therapeutic target Hsp90 and cancer hallmarksYoshihiko Miyata, Hitoshi Nakamoto, Len NeckersCurrent Pharmaceutical Design|August 28, 2012
Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical developmentShiro Soga, Shiro Akinaga, Yukimasa ShiotsuCurrent Pharmaceutical Design|September 1, 2012
Superparamagnetic iron oxide nanoparticles (SPIONs): synthesis and surface modification techniques for use with MRI and other biomedical applicationsSerge Yoffe, Tim Leshuk, Perry Everett, et al.Current Pharmaceutical Design|September 1, 2012
Enterobacteriaceae that produce extended-spectrum β-lactamases and AmpC β-lactamases in the community: the tip of the iceberg?Johann D D PitoutCurrent Pharmaceutical Design|September 7, 2012
Gastric cytoprotection beyond prostaglandins: cellular and molecular mechanisms of gastroprotective and ulcer healing actions of antacidsAndrzej Tarnawski, Amrita Ahluwalia, Michael K JonesCurrent Pharmaceutical Design|September 7, 2012
Novel possible pharmaceutical research tools: stem cells, gene delivery and their combinationGabor Varga, Erzsebet Bori, Karola Kállo, et al.Current Pharmaceutical Design|September 7, 2012
Antimicrobial peptides and colitisSamantha Ho, Charalabos Pothoulakis, Hon Wai KoonCurrent Pharmaceutical Design|September 7, 2012
Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157Predrag Sikiric, Sven Seiwerth, Rudolf Rucman, et al.Current Pharmaceutical Design|August 10, 2012
The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancerAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.Current Pharmaceutical Design|September 15, 2012
Targeting HER receptors in cancerAlberto Ocaña, Atanasio PandiellaPageof 1,008